Shift Bioscience Ltd

Founded in 2017 and based in Cambridge, UK, Shift Bioscience Ltd operates as a biotech company focused on developing therapies to combat age-related diseases through simulation-guided cell rejuvenation. In October 2024, Shift Bioscience Ltd raised USD 16 million led by Business Growth Fund, with participation from F-Prime Capital and Kindred Capital.   Shift Bioscience focuses on leveraging AI-driven cell simulation to develop rejuvenation therapies aimed at reversing the diseases of aging. The company’s platform has discovered six novel gene-based interventions that can reverse cellular aging without inducing stem cell transformation, addressing safety concerns associated with traditional reprogramming methods.

Shift's technology includes the use of advanced cell aging clocks and simulations to test and discover rejuvenation mechanisms, screening molecules and combinations for therapeutic potential. With a team of leading researchers, Shift is working towards creating a single drug family that targets multiple aging-related diseases, aiming to promote long-term health and vitality. The company intends to use the October 2024 funding to advance the development of its cell simulation platform.